• français
    • English
  • English 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Thumbnail
Date
2019
Dewey
Economie sociale
Sujet
Advanced NSCLC; PD-L1 positive; Cost effectiveness; Pembrolizumab; Economics
JEL code
I.I1.I12; I.I1.I11
Journal issue
Lung Cancer
Volume
127
Publication date
2019
Article pages
44-52
Publisher
Elsevier
DOI
http://dx.doi.org/10.1016/j.lungcan.2018.11.008
URI
https://basepub.dauphine.fr/handle/123456789/19589
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Chouaid, Christos
2592 CIC - Biotherapie - CHU Henri Mondor
242232 Service de Pneumologie [CRETEIL - Pneumologie]
Bensimon, Lionel
221125 Merck Sharp & Dohme Corp. [MSD]
Clay, Emilie
221681 Evaluation des systèmes de soins et santé perçue
147877 Creativ-Ceutical France
Millier, Aurélie
147877 Creativ-Ceutical France
203854 Creativ-Ceutical
Levy-Bachelot, Laurie
221125 Merck Sharp & Dohme Corp. [MSD]
Huang, Min
86674 Merck and Co.
Lévy, Pierre
163511 Laboratoire d'Economie de Dauphine [LEDa]
163517 Laboratoire d'Economie et de Gestion des Organisations de Santé [Legos]
559342 Laboratoire d'Economie de Dauphine [LEDa]
Type
Article accepté pour publication ou publié

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.